+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Therapeutic Plasma Exchange Systems Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 100 Pages
  • January 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4987049

The Therapeutic plasma exchange systems market studied was anticipated to grow with a CAGR of nearly 7.5% during the forecast period. The major factor attributing to the growth of the market is an increased number of patients diagnosed with autoimmune diseases, hematology disorders, cardiovascular diseases, and a rise in the geriatric population. For instance, according to the National Institutes of Health report published in the year 2020, the prevalence of myasthenia gravis is increasing in recent decades and affects about 20 per 100,000 people worldwide every year demanding the efficient treatments for the ailments which are likely to fuel the market over the forecast period.

Key Market Trends

The Neurological Disorders by Indication Segment is Expected to Hold the Largest Market Share in the Therapeutic Plasma Exchange Systems Market

  • The Neurological disorders segment is expected to account for the largest revenue over the forecast period. This dominance is owing to the increased demand owing to their proven efficiency in managing neurological conditions such as Guillain-Barre syndrome (GBS), multiple sclerosis and myasthenia gravis. On the other hand, the cardiovascular disorders segment is anticipated to witness the highest growth rate during the forecast period due to increased adoption of TPE as the first line of treatment for various disorders such as arteriosclerosis, rheumatic endocarditis, etc. Furthermore, the technological developments in the segment which increased the applications of TPE in the removal of lipoproteins, fibrinogen, and inflammatory factors, etc, are likely to drive the segment over the forecast period
  • Based on the End-User, the major share of the market is covered by hospitals due to the presence of a huge number of hospitalized patients with cardiac, neurological and renal conditions. Also, the rapid increase in favorable reimbursement policies and rise in the number of physicians shifting from private clinics to large scale hospitals are expected to propel the hospital segment during the forecast period

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the overall therapeutic plasma exchange systems market throughout the forecast period. The dominance is due to a rise in the global prevalence of various autoimmune disorders, a steep rise in the adoption of the lipoprotein apheresis treatment for cardiovascular indications like CAD, hypercholesterolemia strokes and atherosclerosis with an increased rate of cardiac deaths in recent years. For instance, according to The American Heart Association, in 2018, nearly 92.1 million individuals in the U.S. suffered from cardiovascular diseases resulted in higher demand for TPE driving the market in the region. Also, increased availability of advanced technology and established healthcare infrastructures in the region is also likely to fuel the market over the forecast period.

Competitive Landscape

The therapeutic plasma exchange systems market is moderately competitive and consists of several major players. Some of the companies are expanding their market position by adopting various strategies such as acquisitions and mergers, while others are developing new methods for the treatment and introducing new products to maintain their market share. For Instance, In April 2017, Terumo BCT received the first and only CE mark approval for its Spectra Optia Apheresis System to treat Guillain-Barre syndrome (GBS) and myasthenia gravis (MG) using Therapeutic Plasma Exchange in the European Market fueling the market revenue share. Few of the major players currently dominating the industry in terms of revenue are Asahi Kasei Corporation, Baxter International Inc, Terumo Corporation, B. Braun Melsungen AG, and Fresenius Kabi AG

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Global Prevalence of Autoimmune and Cardiac Diseases
4.2.2 Growing R&D Activities and Clinical Trials to Increase the Application in Various Indications
4.3 Market Restraints
4.3.1 High Cost of Treatment and Devices
4.3.2 Lack of Skilled Healthcare Professionals in Emerging Markets
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 Products
5.1.1 Apheresis Machine
5.1.2 Filters
5.1.3 Others
5.2 Indication
5.2.1 Neurological Disorders
5.2.2 Cardiovascular Disorders
5.2.3 Hematology Disorders
5.2.4 Renal Disorders
5.2.5 Others
5.3 End-User
5.3.1 Hospitals
5.3.2 Ambulatory Surgical Centers
5.3.3 Others
5.4 Geography
5.4.1 North America United states Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Asahi Kasei Corporation
6.1.2 Baxter International Inc
6.1.3 B. Braun Melsungen AG
6.1.4 Cerus Corporation
6.1.5 Fresenius Kabi AG
6.1.6 Haemonetics Corporation
6.1.7 Hemacare Corporation
6.1.8 IncMedica S.p.A.
6.1.9 Kawasumi Laboratories
6.1.10 Terumo Corporation

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Asahi Kasei Corporation
  • Baxter International Inc
  • B. Braun Melsungen AG
  • Cerus Corporation
  • Fresenius Kabi AG
  • Haemonetics Corporation
  • Hemacare Corporation
  • IncMedica S.p.A.
  • Kawasumi Laboratories
  • Terumo Corporation